A population study on blood-brain barrier function in 85-year-olds: Relation to Alzheimer's disease and vascular dementia

Neurology

Volumn 50, Issue 4, 1998, Pages 966-971

  Skoog, I ^a   Wallin, A ^b   Fredman, P ^b   Hesse, C ^b   Aevarsson, O ^a   Karlsson, I ^b   Gottfries, C G ^b   Blennow, K ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN E3;

AGE; AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 0031922362     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.4.966     Document Type: Article

References (63)

1. Mooradian A. Effect of aging on the blood-brain barrier. Neurobiol Aging 1988:9:31-39. Review.
2. Milhorat T, Hammock K. Cerebrospinal fluid as reflection of internal milieu of brain. In: Wood JH, ed. Neurobiology of cerebrospinal fluid. New York: Plenum, 1983:1-23.
3. Tourtellotte WW, Potvin AR, Fleming JO, et al. Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate. Neurology 1980;30:240-244.
4. Thompso, EJ. The CSF proteins: a biomedical approach. Amsterdam: Elsevier, 1988.
5. Andersson M, Alvarez-Cermeno J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.
6. Blennow K, Wallin A, Gottfries CG, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 1993;33:129-133.
7. Skoog I. Blood pressure and dementia. In: Hansson L, Birkenhäger WH, eds. Handbook of hypertension. Vol 18. Assessment of hypertensive organ damage. Amsterdam: Elsevier Science BV, 1997:303-331.
8. Olsson Y, Brun A, Englund E. Fundamental pathological lesions in vascular dementia. Acta Neurol Scand 1996;168(suppl 2):31-38.
9. Johansson BB. Pathogenesis of vascular dementia: the possible role of hypertension. Dementia 1994;5:174-176.
10. Johansson BB. Cerebral vascular bed in hyeprtension and consequences for the brain. Hypertension 1984;6(suppl 3):81-86.
11. Hampel H, Muller-Spahn F, Berger C, Haberl A, Ackenheil M, Hock C. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia 1995;6:348-354.
12. Mecocci P, Parnetti L, Reboldi GP, et al. Blood brain barrier in a geriatric population: barrier function in degenerative and vascular dementia. Acta Neurol Scand 1991;84:210-213.
13. Wallin A, Blennow K, Gottfries CG, Svennerholm L. Blood-brain barrier function in vascular dementia. Acta Neurol Scand 1990:81;318-322.
14. Blennow K, Wallin A, Uhlemann C, Gottfries C. White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand 1991;83: 187-193.
15. Pantoni L, Inzitari D, Pracucci G, et al. Cerebrospinal fluid proteins in patients with leucoaraiosis: possible abnormalities in blood-brain barrier function. J Neurol Sci 1993;115:125-131.
16. Lantos PL, Cairns NJ. The neuropathology of Alzheimer's disease. In: Burns A, Levy R, eds. Dementia. London: Chapman and Hall, 1994:185-207.
17. Skoog I, Lernfelt B, Landahl S, et al. A 15-year longitudinal study on blood pressure and dementia. Lancet 1996;347:1141-1145.
18. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC III. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995;131:162-169.
19. Sparks DL, Hunsaker JC III, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990;11:601-607.
20. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-154.
21. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986;19:253-262.
22. De la Monte SM. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol 1989;25: 450-459.
23. Skoog I, Palmertz B, Andreasson L-A. The prevalence of white matter lesions on computed tomography of the brain in demented and non-demented 85-year-olds. J Geriatr Psychiatry Neurol 1994;7:169-175.
24. Glenner GG. Congophilic microangiopathy in the pathogenesis of Alzheimer's syndrome (presenile dementia). Med Hypoth 1979:5:1231-1236.
25. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke 1987;18:311-324.
26. Kalaria RN, Hedera P. β-Amyloid vasoactivity in Alzheimer's disease. Lancet 1996;347:1492-1493. Letter.
27. Perlmutter LS, Chui HC. Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 1990;24:677-686.
28. Kimura T, Hashimura T, Miyakawa T. Observations of microvessels in the brain with Alzheimer's disease by scanning electron microscopy. Jpn J Psych Neurol 1991;45:671-676.
29. Scheibel AB, Duong T, Tomiyasu U. Denervation microangiopathy in senile dementia, Alzheimer type. Alz Dis Assoc Dis 1987;1:19-37.
30. Claudio L. Utrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 1996;91:6-14.
31. Wisniewski HM, Kozlowski PB. Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT). Ann NY Acad Sci 1982;396:119-131.
32. Licandro A, Ferla S, Tavolato B. Alzheimer's disease and senile brains: an immunofluorescence study. Riv Pat Nerv Ment 1983;104:75-87.
33. Mann DMA, Davies JS, Hawkes J, Yates PO. Immunohistochemical staining of senile plaques. Neuropathol Appl Neurobiol 1982;8:55-61.
34. Hardy J, Mann D, Wester P, Winblad B. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging 1986;7:489-502.
35. Kalaria RN, Golde TE, Cohen ML, Younkin SG. Serum amyloid P in Alzheimer's disease. Implications for dysfunction of the blood-brain barrier. Ann NY Acad Sci 1991;640:145-148.
36. Perlmutter LS, Myers MA, Barrón E. Vascular basement membrane components and the lesions of Alzheimer's disease: light and electron microscopic analyses. Microsc Res Technique 1994;28:204-215.
37. Elovaara I, Icén A, Palo J, Erkinjuntti T. CSF in Alzheimer's disease. Studies on blood-brain barrier function and intrathecal protein synthesis. J Neurol Sci 1985:70:73-80.
38. Elovaara I, Seppälä I, Palo J, Sulkava R, Erkinjuntti T. Oligoclonal immunoglobulin bands in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Acta Neurol Scand 1988:77:397-401.
39. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 1990:81;349-351.
40. Kay A, May C, Papadopoulos N, et al. CSF and serum concentration of albumin and IgG in Alzheimer's disease. Neurobiol Aging 1987:8:21-25.
41. Leonardi A, Gandolfo C, Caponetto C, Arata L, Vecchia R. The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid. J Neurol Sci 1985;67: 253-261.
42. Skoog I, Nilsson L, Palmertz B, Andreasson L, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med 1993;328:153-158.
43. Rinder L, Roupe S, Steen B, Svanborg A. Seventy-year-old people in Gothenburg. A population study in an industrialized Swedish city. I. General presentation of the study. Acta Med Scand 1975;198:397-407.
44. Svanborg A. Seventy-year-old people in Gothenburg. A population study in an industrialized Swedish city. II. General presentation of social and medical conditions. Acta Med Scand 1977;611(suppl 2):3-37.
45. Aevarsson O, Skoog I. A population-based study on the incidence of dementia disorders between 85 and 88 years of age. J Am Geriatr Soc 1996;44:1455-1460.
46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987.
47. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-944.
48. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993;43: 250-260.
49. Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972:29(suppl 124):21-37.
50. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest 1977:37:391-396.
51. Kane JW, Gowland G. A method for the identification of apolipoprotein E isoforms employing chemical precipitation and flat bed isoelectric focusing in agarose. Ann Clin Biochem 1986;23:509-513.
52. Cox DR, Hinkley DV. Theoretical statistics. New York: Halsted Press, 1974.
53. SAS/STAT. Guide for personal computers. Version 6 Edition. Cary, NC: SAS Institute, 1987.
54. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol (Berlin) 1982:57: 239-242.
55. Lindsberg PJ, Öhman J, Lehto T, et al. Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol 1996;40:587-596.
56. Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta Neuropathol (Berlin) 1984;62:178-184.
57. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996;380:168-171.
58. Harik SI, McGunigal T. The protective influence of the locus ceruleus on the blood-brain barrier. Ann Neurol 1984;15: 568-574.
59. Hornig CR, Busse O, Buettner T, Dorndorf W, Agnoli A, Akengin Z. CT contrast enhancement on brain scans and blood-CSF barrier disturbances in cerebral ischemic infarction. Stroke 1985;16:268-273.
60. Rapoport S. Blood-brain barrier in physiology and medicine. New York: Raven Press, 1976:129-152.
61. Baloh RW, Vinters HV. White matter lesions and disequilibrium in older people. II. Clinicopathologic correlation. Arch Neurol 1995;52:975-981.
62. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
63. Premkumar DRD, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-∈4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996;148:2083-2095.